Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8NODR)

• Drug Name: ATI-502 Drug Info
• Synonyms: ifidancitinib; UNII-R105E71J13; R105E71J13; A-301; 5-[[2-(4-fluoro-3-methoxy-5-methylanilino)-5-methylpyrimidin-4-yl]amino]-3H-1,3-benzoxazol-2-one; Ifidancitinib [INN]; SCHEMBL342002; CHEMBL4594441; GTPL10638; 2(3H)-Benzoxazolone, 5-((2-((4-fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-; 5-((2-((4-Fluoro-3-methoxy-5-methylphenyl)amino)-5-methyl-4-pyrimidinyl)amino)-2(3H)-benzoxazolone; 5-((2-(4-Fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-yl)amino)benzo(d)oxazol-2(3H)-one; 5-(2-(4-fluoro-3-methoxy-5-methylphenylamino)-5-methylpyrimidin-4-ylamino)benzo[d]oxazol-2(3h)-one

Indication

Disease Entry	ICD 11	Status	REF
Alopecia	ED70	Phase 2	[1]
Atopic dermatitis	EA80	Phase 2	[1]
Vitiligo	ED63.0	Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 46851625
  CAS Number: CAS 1236667-40-5
  TTD Drug ID: DM8NODR

Molecule-Related Drug Atlas

Drug(s) Targeting Janus kinase 3 (JAK-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofacitinib	DMBS370	Rheumatoid arthritis	FA20	Approved	[3]
Ritlecitinib	DMYKNME	Alopecia areata	ED70.2	Approved	[2]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[4]
VX-509	DM2U3MX	Rheumatoid arthritis	FA20	Phase 2/3	[5]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[2]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[6]
TD-8236	DMTOMJN	Asthma	CA23	Phase 2	[7]
ALXN2075	DM1BSD8	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[8]
SNA-125	DM8L1GJ	Atopic dermatitis	EA80	Phase 1	[2]
GDC-0214	DMCNSII	Asthma	CA23	Phase 1	[9]

Drug(s) Targeting Tyrosine-protein kinase (PTK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[10]
Abrocitinib	DM8J29L	Atopic dermatitis	EA80	Approved	[2]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[11]
Masitinib	DMRSNEU	Amyotrophic lateral sclerosis	8B60.0	Phase 3	[12]
KD019	DMEFW3G	Brain metastases	2D50	Phase 2	[12]
LEO 124249	DM7W0JE	Asthma	CA23	Phase 2	[2]
TD-1473	DMJG7AY	Ulcerative colitis	DD71	Phase 1	[11]
Aminotriazolopyridine derivative 1	DMW2LZ0	N. A.	N. A.	Patented	[13]
Imidazo[4,5-c]pyridine derivative 2	DMFDRJT	N. A.	N. A.	Patented	[13]
PMID27774824-Compound-Figure11Example1up	DMH1W8F	N. A.	N. A.	Patented	[13]

Drug(s) Targeting Janus kinase 1 (JAK-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Baricitinib	DM4ONW5	Rheumatoid arthritis	FA20	Approved	[5]
Ruxolitinib	DM7Q98D	Essential thrombocythemia	3B63.1Z	Approved	[14]
Upadacitinib	DM32B5U	Rheumatoid arthritis	FA20	Approved	[15]
ASP-015K	DMZ1UOI	Psoriasis vulgaris	EA90	Phase 3	[16]
SHR0302	DMUL8ZT	Ulcerative colitis	DD71	Phase 3	[17]
Cerdulatinib	DMSCR2H	B-cell lymphoma	2A86	Phase 2	[2]
CTP-543	DM3SYOK	Alopecia	ED70	Phase 2	[11]
INCB039110	DMD9RV3	Malignant neoplasm	2A00-2F9Z	Phase 2	[16]
PF-06700841	DMMGSFV	Asthma	CA23	Phase 2	[2]
ATI-501	DMTY6OF	Alopecia	ED70	Phase 2	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Janus kinase 1 (JAK-1)	TT6DM01	JAK1_HUMAN	Inhibitor	[1]
Janus kinase 3 (JAK-3)	TTT7PJU	JAK3_HUMAN	Inhibitor	[1]
Tyrosine-protein kinase (PTK)	TTJSQEF	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT03759340) ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2049).
• [5] Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77.
• [6] Clinical pipeline report, company report or official report of Aclaris Therapeutics.
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [8] The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2017 May 1;23(9):2313-2324.
• [9] Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A?randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021 Sep;148(3):783-789.
• [10] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [11] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
• [14] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2047).
• [17] Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial. Am J Clin Dermatol. 2021 Nov;22(6):877-889.